Continuing push beyond Covid-19 vaccines, Moderna partners with 'CAR-M' biotech on in vivo cancer cell therapies
Since coming into a massive windfall with its Covid-19 vaccines, Moderna has been looking for ways to expand its mRNA technologies into other promising areas. On Monday, the biotech took its next step toward that goal.
Moderna is partnering with Carisma Therapeutics on a huge slate of “CAR-M” programs to treat cancer, the companies announced Monday morning, promising $45 million upfront and $35 million in equity. Though the amount of milestones was not specified, the biotechs noted Moderna has the option to nominate up to 12 targets for development.